|
Q-Med is a medical device company that develops, manufactures, markets and sells high quality medical implants for esthetic and medical use. The majority of the products are based on the company’s patented technology, NASHA™, for the production of stabilized non-animal hyaluronic acid.
The company today has approximately 650 co-workers in 20 countries, with approximately 400 at the company's head office and production facility in Uppsala. Q-Med AB is listed in the Mid Cap segment of the NASDAQ OMX Nordic.
Q-Med has as its overall objective high growth combined with good profitability. Q-Med shall consistently strive to meet its customers’ and other stakeholders’ expectations and needs, through constant improvements in quality and constant training. Q-Med also strives to give its shareholders a competitive return on their invested capital both in the short and long term.
The product portfolio consists of:
Esthetics
Restylane® is an internationally leading product family for esthetic beauty treatments. The products are used for smoothing out wrinkles and lines, for filling out and shaping lips, defining facial contours and improving the quality of the skin. Restylane is the world’s most documented injectable hyaluronic acid product for esthetic use and has been on the market for more than 13 years. Over 11 million Restylane treatments have been carried out all over the world.
Macrolane™ VRF is the first series of products on the market that makes it possible to shape the body without surgery. When Macrolane is injected, the gel can enlarge breasts, create volume and smooth out defects on the body. The advantages of the treatment are immediate and long-lasting, without being permanent. The hyaluronic acid in Macrolane is similar to that of the body and is therefore broken down naturally.
Hospital Healthcare
Deflux® for the treatment of a malformation of the urinary bladder in children. Durolane™ for the treatment of osteoarthritis of the knee and hip. Solesta™ for the treatment of fecal incontinence.
|